November 17, 2014 | Results of a seven year cardiac outcomes study were announced today. The IMPROVE-IT trial of Merck's Vytorin versus simvastatin showed that Vytorin does improve outcomes. The results were "modest" but they were there. The trial results were released days after a sequencing study showed that deactivating the protein-target for Vytorin can lower risk of heart attack by 53%. The two results aren't identical, but the drug study result could be good news for LDL-targeting drug research. Forbes